KZR Stock Price, Kezar Life Sciences Inc Quote, Chart

Market Summary

USD0.76-0.01

Market Closed

-1.30%

KZR Stock Price

View Fullscreen

KZR RSI Chart

KZR Valuation

Market Cap

55.3M

Price/Earnings (Trailing)

-0.55

Price/Sales (Trailing)

7.9

Price/Free Cashflow

-0.65

KZR Price/Sales (Trailing)

KZR Profitability

Return on Equity

-59.92%

Return on Assets

-50.89%

Free Cashflow Yield

-153.92%

KZR Fundamentals

KZR Revenue

Revenue (TTM)

7.0M

Rev. Growth (Qtr)

-100%

KZR Earnings

Earnings (TTM)

-101.3M

Earnings Growth (Yr)

2.44%

Earnings Growth (Qtr)

32.86%

Breaking Down KZR Revenue

Last 7 days

-1.3%

Last 30 days

-7.3%

Last 90 days

-9.5%

Trailing 12 Months

-71.2%

How does KZR drawdown profile look like?

KZR Financial Health

Current Ratio

11.49

Debt/Equity

0.05

Debt/Cashflow

-9.47

KZR Investor Care

Shares Dilution (1Y)

0.54%

Diluted EPS (TTM)

-1.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	7.0M
2022	0	0	0	0
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kezar Life Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 15, 2023	morningside venture investments ltd	gifted	-	-	-3,500,000	-
Jul 20, 2023	kirk christopher j.	acquired	44,055	0.9	48,950	-
Feb 06, 2023	morningside venture investments ltd	sold	-275,320	6.883	-40,000	-
Feb 03, 2023	morningside venture investments ltd	sold	-178,650	7.146	-25,000	-
Feb 02, 2023	morningside venture investments ltd	sold	-359,500	7.19	-50,000	-
Feb 01, 2023	morningside venture investments ltd	sold	-278,000	6.95	-40,000	-
Jan 31, 2023	morningside venture investments ltd	sold	-212,400	7.08	-30,000	-
Jan 30, 2023	morningside venture investments ltd	sold	-207,300	6.91	-30,000	-
Jan 25, 2023	morningside venture investments ltd	sold	-342,500	6.85	-50,000	-
Jan 24, 2023	morningside venture investments ltd	sold	-558,400	6.98	-80,000	-

Which funds bought or sold KZR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Ikarian Capital, LLC	added	1.83	-25,019	783,484	0.09%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	sold off	-100	-11,129	-	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-64.61	-43,629	22,151	-%
May 15, 2024	Prosight Management, LP	reduced	-71.37	-2,319,540	868,780	0.24%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	-88,257	1,737,380	0.03%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-31.53	-52,344	97,914	-%
May 15, 2024	IRONWOOD INVESTMENT MANAGEMENT LLC	added	11.39	1,431	25,256	0.01%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	7.07	21,840	1,174,110	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	added	124	330,617	621,151	0.06%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-72.09	-2,036,990	736,583	-%

Are Funds Buying or Selling KZR?

Are funds buying KZR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KZR

No. of Funds

Unveiling Kezar Life Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	barclays plc	5.27%	3,827,356	SC 13G
Feb 14, 2024	avidity partners management lp	6.9%	5,025,454	SC 13G/A
Feb 14, 2024	orbimed advisors llc	2.7%	1,927,000	SC 13G/A
Feb 13, 2024	prosight management, lp	4.6%	3,365,333	SC 13G/A
Feb 13, 2024	suvretta capital management, llc	9.9%	7,167,591	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	4,817,266	SC 13G/A
Jan 23, 2024	state street corp	1.54%	1,116,052	SC 13G/A
Jan 22, 2024	millennium management llc	4.0%	2,927,563	SC 13G/A
Aug 17, 2023	morningside venture investments ltd	2.68%	1,947,993	SC 13D/A
Jun 21, 2023	millennium management llc	5.2%	3,780,534	SC 13G

Recent SEC filings of Kezar Life Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 16, 2024	PRE 14A	PRE 14A
Mar 22, 2024	424B5	Prospectus Filed
Mar 14, 2024	S-8	Employee Benefits Plan
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	10-K	Annual Report

Peers (Alternatives to Kezar Life Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Kezar Life Sciences Inc News

Latest updates

Kezar Life Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4
Revenue	-100.0%	-	7,000	-	-	-	-
Operating Expenses	6.3%	34,589	32,527	26,784	24,524	20,034	14,103
S&GA Expenses	-34.5%	5,760	8,789	5,785	6,206	5,175	4,322
R&D Expenses	-4.6%	22,642	23,738	20,999	18,318	14,859	9,781
Interest Expenses	0.8%	399	396	385	370	349	159
Net Income	-39.6%	-32,260	-23,103	-24,308	-22,199	-18,181	-14,212
Net Income Margin	-Infinity%	-14.55*	-	-	-	-	-
Free Cashflow	6.7%	-18,981	-20,341	-22,976	-21,157	-16,226	-11,347

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.0%	199	221	249	263	284	300	305	318	252	218	131	140	152	152	161	168	135	90.00	98.00	105	113
Current Assets	-10.3%	186	207	231	244	265	286	299	311	246	212	125	133	146	145	154	161	127	81.00	89.00	96.00	104
Cash Equivalents	-6.9%	33.00	35.00	26.00	28.00	36.00	40.00	64.00	105	39.00	63.00	57.00	26.00	23.00	21.00	13.00	17.00	21.00	15.00	20.00	13.00	18.00
Net PPE	-6.6%	4.00	4.00	4.00	5.00	5.00	3.00	3.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	5.00	5.00	5.00
Liabilities	-10.9%	30.00	34.00	33.00	31.00	32.00	30.00	22.00	20.00	20.00	21.00	11.00	10.00	12.00	11.00	11.00	10.00	12.00	11.00	11.00	11.00	11.00
Current Liabilities	-8.9%	16.00	18.00	17.00	14.00	14.00	11.00	10.00	8.00	7.00	8.00	8.00	6.00	8.00	6.00	6.00	5.00	7.00	6.00	5.00	5.00	5.00
Long Term Debt	-12.3%	9.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-9.8%	169	188	216	232	252	270	283	297	232	197	119	130	141	141	150	158	123	78.00	86.00	95.00	102
Retained Earnings	-6.2%	-372	-350	-318	-295	-271	-248	-230	-212	-196	-180	-166	-151	-139	-126	-115	-103	-94.30	-84.28	-74.70	-65.56	-56.84
Additional Paid-In Capital	0.6%	542	538	535	528	524	520	515	511	430	378	286	282	280	267	265	262	217	163	161	160	159
Shares Outstanding	0.0%	73.00	73.00	73.00	73.00	71.00	68.00	72.00	64.00	61.00	53.00	52.00	51.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	173	-	-	-	551	-	-	-	252	-	-	-	174	-	-	-	119	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-20.5%	-22,862	-18,980	-20,205	-21,600	-20,860	-15,883	-16,360	-13,289	-13,314	-11,081	-9,954	-13,045	-8,357	-9,307	-9,250	-10,091	-8,301	-7,210	-8,255	-7,712	-6,700
Share Based Compensation	6.6%	3,434	3,220	6,634	4,020	4,263	3,817	3,787	3,298	3,104	1,853	1,878	1,937	1,928	1,280	1,271	1,219	1,173	1,007	1,090	1,009	901
Cashflow From Investing	-26.8%	20,408	27,878	18,574	13,203	16,391	-8,661	-24,708	1,510	-59,533	-82,491	38,484	16,250	-687	17,318	2,790	-37,276	-39,330	1,678	15,623	2,142	976
Cashflow From Financing	-100.0%	-	59.00	43.00	382	154	506	185	78,322	48,848	99,356	2,212	282	10,735	317	1,962	43,995	53,368	80.00	8.00	180	4.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KZR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 17,172	$ 18,318
General and administrative	6,539	6,206
Total operating expenses	23,711	24,524
Loss from operations	(23,711)	(24,524)
Interest income	2,453	2,695
Interest expense	(400)	(370)
Net loss	$ (21,658)	$ (22,199)
Net loss per common share, Basic	$ (0.3)	$ (0.31)
Net loss per common share, Diluted	$ (0.3)	$ (0.31)
Weighted-average shares used to compute net loss per common share, Basic	72,799,910	72,328,231
Weighted-average shares used to compute net loss per common share, Diluted	72,799,910	72,328,231

KZR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 33,032	$ 35,493
Marketable securities	146,766	165,879
Prepaid expenses and other current assets	5,815	5,578
Total current assets	185,613	206,950
Property and equipment, net	3,652	3,912
Operating lease right-of-use asset	4,364	4,778
Other assets	5,501	5,595
Total assets	199,130	221,235
Current liabilities:
Accounts payable	5,059	8,251
Accrued and other current liabilities	6,664	6,481
Operating lease liabilities, current	3,134	3,012
Debt, current	1,304	0
Total current liabilities	16,161	17,744
Operating lease liabilities, noncurrent	5,019	5,852
Debt, noncurrent	8,829	10,069
Total liabilities	30,009	33,665
Stockholders' equity:
Common stock, $0.001 par value, 250,000,000 and 250,000,000 shares authorized as of March 31, 2024 (unaudited) and December 31, 2023, respectively; 72,801,359 and 72,779,077 shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023, respectively	73	73
Preferred stock, $0.001 par value, 10,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2024 (unaudited) and December 31, 2023	0	0
Additional paid-in capital	541,824	538,390
Accumulated other comprehensive loss	(355)	(130)
Accumulated deficit	(372,421)	(350,763)
Total stockholders' equity	169,121	187,570
Total liabilities and stockholders' equity	$ 199,130	$ 221,235

About Kezar Life Sciences Inc

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

CEO	Mr. John Franklin Fowler
WEBSITE	kezarlifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	84

Kezar Life Sciences Inc Frequently Asked Questions

What is the ticker symbol for Kezar Life Sciences Inc? What does KZR stand for in stocks?

KZR is the stock ticker symbol of Kezar Life Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kezar Life Sciences Inc (KZR)?

As of Fri May 17 2024, market cap of Kezar Life Sciences Inc is 55.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers.

What is the fair value of KZR stock?

You can check KZR's fair value in chart for subscribers. The fair value of Kezar Life Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kezar Life Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KZR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kezar Life Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether KZR is over valued or under valued. Whether Kezar Life Sciences Inc is cheap or expensive depends on the assumptions which impact Kezar Life Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KZR.

What is Kezar Life Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, KZR's PE ratio (Price to Earnings) is -0.55 and Price to Sales (PS) ratio is 7.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KZR PE ratio will change depending on the future growth rate expectations of investors.